Celebrity red carpet appearances at the SAG Awards have reignited concerns about their noticeably slimmer figures and fueled ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

Ozempic and Wegovy are both weekly injections. Ozempic is sold in injection pens containing 0.25 and 0.5mg doses, 1mg doses, and 2mg doses (the 2mg dose pens are not available in South Africa).

The phase 3b STEP UP trial in more than 1,400 patients compared a 7.2mg weekly subcutaneous injection of semaglutide to the standard 2.6mg weekly dose sold as Wegovy or a matched placebo.

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, ...

Its medicines, most notably Ozempic, Rybelsus, and Wegovy have helped improve the lives ... results from a trial for Semaglutide 7.2 mg, demonstrating superior weight loss compared to placebo.